Alpharadin radium-223: Phase IIa data

Top-line data from the single-arm, open-label, European Phase IIa BC1-09 trial in 23 patients showed that 50 kBq/kg IV Alpharadin given once every 4 weeks for 16 weeks reduced levels of 2 biomarkers o...